Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma

Tzeon Jye Chiou, Teng Hsu Wang, Tsu Yi Chao, Sheng Fung Lin, Jih Luh Tang, Tsai Yun Chen, Ming Chih Chang, Erh Jung Hsueh, Po Min Chen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The potential synergistic anti-myeloma effect for thalidomide combining with interferon alpha was not yet clear clinically. From March 2001 to January 2004, a total of 28 heavily pretreated multiple myleoma (MM) patients were enrolled in this open-labeled, randomized Phase II study. Patients with refractory MM were randomized to receive either thalidomide alone (200 mg/day up to the maximum dose 800 mg/day, arm B) or the combination of thalidomide and interferon alpha (3 MIU/m2 subcutaneous injection 3 times weekly, arm A). The objective of this study was to compare the safety and efficacy of thalidomide alone to combined regimen. The patients' characteristics were similar between the 2 arms. However, the average treatment duration was significantly longer in the arm B than the arm A (236 days versus 101 days, p = 0.029). Serum levels of paraprotein decline ≥ 25 percent were obtained in 6 of 12 patients (50.0 percent) treated with arm B and 3 of the 16 patients (18.8 percent) treated with arm A. The estimated time to event was 7.9 months (95 percent confidence interval [95%CI], 0.5-15.4) for arm B and 1.5 months (95%CI, 0.0-3.4) for arm A (log-rank test, p = 0.0193). The major adverse events in both arms consisted of neutropenia, anemia, thrombocytopenia, constipation, somnolence, and skin rash. Our study showed that thalidomide alone was effective and tolerated in patients with relapsed or refractory MM. The thalidomide combined with interferon alpha resulted in a lower frequency of paraprotein response, shorter treatment-duration and 25 percent of patients' refusing rate. It may be concluded that the combined regimen is not well tolerated in our patients and needed to be further evaluated in the future.

Original languageEnglish
Pages (from-to)140-147
Number of pages8
JournalCancer Investigation
Volume25
Issue number3
DOIs
Publication statusPublished - Apr 2007
Externally publishedYes

Fingerprint

Thalidomide
Multiple Myeloma
Interferon-alpha
Paraproteins
Confidence Intervals
Subcutaneous Injections
Constipation
Exanthema
Neutropenia
Thrombocytopenia
Anemia
Safety
Therapeutics
Serum

Keywords

  • Adverse effect
  • Interferon-alpha
  • Paraprotein response
  • Refractory multiple myeloma
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. / Chiou, Tzeon Jye; Wang, Teng Hsu; Chao, Tsu Yi; Lin, Sheng Fung; Tang, Jih Luh; Chen, Tsai Yun; Chang, Ming Chih; Hsueh, Erh Jung; Chen, Po Min.

In: Cancer Investigation, Vol. 25, No. 3, 04.2007, p. 140-147.

Research output: Contribution to journalArticle

Chiou, Tzeon Jye ; Wang, Teng Hsu ; Chao, Tsu Yi ; Lin, Sheng Fung ; Tang, Jih Luh ; Chen, Tsai Yun ; Chang, Ming Chih ; Hsueh, Erh Jung ; Chen, Po Min. / Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. In: Cancer Investigation. 2007 ; Vol. 25, No. 3. pp. 140-147.
@article{0fe8fb2b2378473ea85f8b1025412bf9,
title = "Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma",
abstract = "The potential synergistic anti-myeloma effect for thalidomide combining with interferon alpha was not yet clear clinically. From March 2001 to January 2004, a total of 28 heavily pretreated multiple myleoma (MM) patients were enrolled in this open-labeled, randomized Phase II study. Patients with refractory MM were randomized to receive either thalidomide alone (200 mg/day up to the maximum dose 800 mg/day, arm B) or the combination of thalidomide and interferon alpha (3 MIU/m2 subcutaneous injection 3 times weekly, arm A). The objective of this study was to compare the safety and efficacy of thalidomide alone to combined regimen. The patients' characteristics were similar between the 2 arms. However, the average treatment duration was significantly longer in the arm B than the arm A (236 days versus 101 days, p = 0.029). Serum levels of paraprotein decline ≥ 25 percent were obtained in 6 of 12 patients (50.0 percent) treated with arm B and 3 of the 16 patients (18.8 percent) treated with arm A. The estimated time to event was 7.9 months (95 percent confidence interval [95{\%}CI], 0.5-15.4) for arm B and 1.5 months (95{\%}CI, 0.0-3.4) for arm A (log-rank test, p = 0.0193). The major adverse events in both arms consisted of neutropenia, anemia, thrombocytopenia, constipation, somnolence, and skin rash. Our study showed that thalidomide alone was effective and tolerated in patients with relapsed or refractory MM. The thalidomide combined with interferon alpha resulted in a lower frequency of paraprotein response, shorter treatment-duration and 25 percent of patients' refusing rate. It may be concluded that the combined regimen is not well tolerated in our patients and needed to be further evaluated in the future.",
keywords = "Adverse effect, Interferon-alpha, Paraprotein response, Refractory multiple myeloma, Thalidomide",
author = "Chiou, {Tzeon Jye} and Wang, {Teng Hsu} and Chao, {Tsu Yi} and Lin, {Sheng Fung} and Tang, {Jih Luh} and Chen, {Tsai Yun} and Chang, {Ming Chih} and Hsueh, {Erh Jung} and Chen, {Po Min}",
year = "2007",
month = "4",
doi = "10.1080/07357900701208808",
language = "English",
volume = "25",
pages = "140--147",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma

AU - Chiou, Tzeon Jye

AU - Wang, Teng Hsu

AU - Chao, Tsu Yi

AU - Lin, Sheng Fung

AU - Tang, Jih Luh

AU - Chen, Tsai Yun

AU - Chang, Ming Chih

AU - Hsueh, Erh Jung

AU - Chen, Po Min

PY - 2007/4

Y1 - 2007/4

N2 - The potential synergistic anti-myeloma effect for thalidomide combining with interferon alpha was not yet clear clinically. From March 2001 to January 2004, a total of 28 heavily pretreated multiple myleoma (MM) patients were enrolled in this open-labeled, randomized Phase II study. Patients with refractory MM were randomized to receive either thalidomide alone (200 mg/day up to the maximum dose 800 mg/day, arm B) or the combination of thalidomide and interferon alpha (3 MIU/m2 subcutaneous injection 3 times weekly, arm A). The objective of this study was to compare the safety and efficacy of thalidomide alone to combined regimen. The patients' characteristics were similar between the 2 arms. However, the average treatment duration was significantly longer in the arm B than the arm A (236 days versus 101 days, p = 0.029). Serum levels of paraprotein decline ≥ 25 percent were obtained in 6 of 12 patients (50.0 percent) treated with arm B and 3 of the 16 patients (18.8 percent) treated with arm A. The estimated time to event was 7.9 months (95 percent confidence interval [95%CI], 0.5-15.4) for arm B and 1.5 months (95%CI, 0.0-3.4) for arm A (log-rank test, p = 0.0193). The major adverse events in both arms consisted of neutropenia, anemia, thrombocytopenia, constipation, somnolence, and skin rash. Our study showed that thalidomide alone was effective and tolerated in patients with relapsed or refractory MM. The thalidomide combined with interferon alpha resulted in a lower frequency of paraprotein response, shorter treatment-duration and 25 percent of patients' refusing rate. It may be concluded that the combined regimen is not well tolerated in our patients and needed to be further evaluated in the future.

AB - The potential synergistic anti-myeloma effect for thalidomide combining with interferon alpha was not yet clear clinically. From March 2001 to January 2004, a total of 28 heavily pretreated multiple myleoma (MM) patients were enrolled in this open-labeled, randomized Phase II study. Patients with refractory MM were randomized to receive either thalidomide alone (200 mg/day up to the maximum dose 800 mg/day, arm B) or the combination of thalidomide and interferon alpha (3 MIU/m2 subcutaneous injection 3 times weekly, arm A). The objective of this study was to compare the safety and efficacy of thalidomide alone to combined regimen. The patients' characteristics were similar between the 2 arms. However, the average treatment duration was significantly longer in the arm B than the arm A (236 days versus 101 days, p = 0.029). Serum levels of paraprotein decline ≥ 25 percent were obtained in 6 of 12 patients (50.0 percent) treated with arm B and 3 of the 16 patients (18.8 percent) treated with arm A. The estimated time to event was 7.9 months (95 percent confidence interval [95%CI], 0.5-15.4) for arm B and 1.5 months (95%CI, 0.0-3.4) for arm A (log-rank test, p = 0.0193). The major adverse events in both arms consisted of neutropenia, anemia, thrombocytopenia, constipation, somnolence, and skin rash. Our study showed that thalidomide alone was effective and tolerated in patients with relapsed or refractory MM. The thalidomide combined with interferon alpha resulted in a lower frequency of paraprotein response, shorter treatment-duration and 25 percent of patients' refusing rate. It may be concluded that the combined regimen is not well tolerated in our patients and needed to be further evaluated in the future.

KW - Adverse effect

KW - Interferon-alpha

KW - Paraprotein response

KW - Refractory multiple myeloma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=34347266571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347266571&partnerID=8YFLogxK

U2 - 10.1080/07357900701208808

DO - 10.1080/07357900701208808

M3 - Article

VL - 25

SP - 140

EP - 147

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -